OliX Pharmaceuticals,Inc

KOSDAQ 226950.KQ

OliX Pharmaceuticals,Inc Return on Capital Employed (ROCE) for the year ending December 31, 2023: -14.31%

OliX Pharmaceuticals,Inc Return on Capital Employed (ROCE) is -14.31% for the year ending December 31, 2023, a 49.09% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

OliX Pharmaceuticals,Inc Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -28.11%, a 52.77% change year over year.
OliX Pharmaceuticals,Inc Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -59.53%, a -117.57% change year over year.
OliX Pharmaceuticals,Inc Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -27.36%, a 18.42% change year over year.
OliX Pharmaceuticals,Inc Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -33.54%, a -140.71% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

KOSDAQ: 226950.KQ

OliX Pharmaceuticals,Inc

CEO	Mr. Dong-Ki Lee Ph.D.
IPO Date	July 18, 2018
Location	South Korea
Headquarters	#1014 Gwanggyo Ace Tower1, 17
Employees	72
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.

Key trends

Past 5 years